⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 1, 2026European Journal of NeurologyOpen Access

A Real‐World Study of CGRP Monoclonal Antibodies for Migraine: Long‐Term Effectiveness and Treatment Adherence

Keisuke Suzuki Shiho Suzuki S. Kobayashi Mukuto Shioda Hiroaki Fujita Yasuo Haruyama K. Hirata

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the long-term effectiveness and treatment adherence of CGRP monoclonal antibodies for migraine.
Real-world observational study design
Assessment of migraine frequency over time
Evaluation of adverse effects and patient tolerability
CGRP monoclonal antibodies significantly reduced migraine frequency over the long term
Patients reported favorable tolerability throughout the treatment period

Implication

Real-world study shows long-term reduction in migraine frequency with CGRP monoclonal antibodies, suggesting effective treatment adherence.

Abstract

CGRP mAbs were associated with a long-term reduction in migraine frequency and favorable tolerability.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Suzuki et al. (2026) studied this question.

synapsesocial.com/papers/69b257a296eeacc4fcec6742 https://doi.org/10.1111/ene.70562

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of CGRP monoclonal antibodies in chronic migraine: a systematic review integrating randomized and real-world evidenceRCT · 2026
2Patient Adherence and Long-Term Tolerability of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention: A Systematic ReviewSystematic Review · 2025 · 6 citations
3Anti-CGRP monoclonal antibodies for chronic migraine with medication-overuse headache: a conservative meta-analysisMeta-Analysis · 2026 · 2 citations
4Comparative effectiveness and tolerability of calcitonin gene‐related peptide (<scp>CGRP)</scp> monoclonal antibodies and <scp>onabotulinumtoxinA</scp> in chronic migraine: A multicenter, real‐world study in Taiwan2024 · 12 citations
5Cgrp Monoclonal Antibodies: Key Lessons from Real World Evidence2024 · 4 citations

More related papers

SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway–targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials2025
Real world effectiveness of anti-CGRP monoclonal antibodies over three consecutive one-year treatment cycles: An intention-to-treat analysis2025
Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients2024

More from European Journal of Neurology

Continuous Versus Routine EEG in Critically Ill Patients Without Primary Neurologic Condition: Analysis of a Randomized Controlled TrialMon,
Dissociating Fatigue and Fatigability in Multiple Sclerosis: The Role of Cognitive Processing SpeedTue,